It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Smooth muscle cells (SMC) in blood vessels are normally growth quiescent and transcriptionally inactive. Our objective was to understand promoter usage and dynamics in SMC acutely exposed to a prototypic growth factor or pro-inflammatory cytokine. Using cap analysis gene expression (FANTOM5 project) we report differences in promoter dynamics for immediate-early genes (IEG) and other genes when SMC are exposed to fibroblast growth factor-2 or interleukin-1β. Of the 1871 promoters responding to FGF2 or IL-1β considerably more responded to FGF2 (68.4%) than IL-1β (18.5%) and 13.2% responded to both. Expression clustering reveals sets of genes induced, repressed or unchanged. Among IEG responding rapidly to FGF2 or IL-1β were FOS, FOSB and EGR-1, which mediates human SMC migration. Motif activity response analysis (MARA) indicates most transcription factor binding motifs in response to FGF2 were associated with a sharp induction at 1 h, whereas in response to IL-1β, most motifs were associated with a biphasic change peaking generally later. MARA revealed motifs for FOS_FOS{B,L1}_JUN{B,D} and EGR-1..3 in the cluster peaking 1 h after FGF2 exposure whereas these motifs were in clusters peaking 1 h or later in response to IL-1β. Our findings interrogating CAGE data demonstrate important differences in promoter usage and dynamics in SMC exposed to FGF2 or IL-1β.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Vascular Biology and Translational Research, School of Medical Sciences, University of New South Wales, Sydney, Australia
2 RIKEN Center for Life Science Technologies (Division of Genomic Technologies) (CLST DGT), Yokohama, Kanagawa, Japan; Department of Biosciences and Nutrition and Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden; RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan
3 RIKEN Center for Life Science Technologies (Division of Genomic Technologies) (CLST DGT), Yokohama, Kanagawa, Japan; RIKEN Omics Science Center (OSC), Tsurumi-ku Yokohama, Japan; RIKEN Preventive Medicine and Diagnosis Innovation Program (PMI), Wako-shi, Saitama, Japan; Preventive Medicine and Applied Genomics Unit, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan
4 RIKEN Center for Life Science Technologies (Division of Genomic Technologies) (CLST DGT), Yokohama, Kanagawa, Japan; RIKEN Omics Science Center (OSC), Tsurumi-ku Yokohama, Japan; RIKEN Preventive Medicine and Diagnosis Innovation Program (PMI), Wako-shi, Saitama, Japan
5 RIKEN Center for Life Science Technologies (Division of Genomic Technologies) (CLST DGT), Yokohama, Kanagawa, Japan; RIKEN Omics Science Center (OSC), Tsurumi-ku Yokohama, Japan; Laboratory for Applied Computational Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan
6 RIKEN Center for Life Science Technologies (Division of Genomic Technologies) (CLST DGT), Yokohama, Kanagawa, Japan; RIKEN Omics Science Center (OSC), Tsurumi-ku Yokohama, Japan; Laboratory for Transcriptome Technology, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan
7 RIKEN Omics Science Center (OSC), Tsurumi-ku Yokohama, Japan; RIKEN Preventive Medicine and Diagnosis Innovation Program (PMI), Wako-shi, Saitama, Japan
8 RIKEN Center for Life Science Technologies (Division of Genomic Technologies) (CLST DGT), Yokohama, Kanagawa, Japan; RIKEN Omics Science Center (OSC), Tsurumi-ku Yokohama, Japan; Laboratory for Applied Regulatory Genomics Network Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan